A String of Bold Acquisitions
The Adverum deal is the latest in a series of strategic moves by Lilly to broaden its genetic medicine pipeline. In June 2025, the company struck a $1.3 billion agreement to acquire Verve Therapeutics, and previously absorbed Akouos Inc. in 2022 to enhance its gene therapy platform.
With this acquisition, Lilly reinforces its trajectory toward pioneering advanced therapies that merge genetics, vision science, and precision medicine — reshaping the pharmaceutical landscape for decades to come.
Legal Advisors
-
For Eli Lilly: Ropes & Gray LLP — Partners Emily Oldshue, Dan Coyne, Renata Ferrari, Pamela Glazier, Geoffrey Lin, Cristi Schwarzman, David Kaye, David Peloquin, and Greg Levine.
-
For Adverum: Cooley LLP — Partners Bill Roegge and Jason Kent.
